Sign In
Buy KYTX
$7.82
-0.0800 (-1.01%)
At Close: Jun 03, 2026
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
08:06am, Tuesday, 16'th Dec 2025
U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Tuesday.
Traders Buy High Volume of Kyverna Therapeutics Call Options (NASDAQ:KYTX)
01:29am, Tuesday, 16'th Dec 2025
Kyverna Therapeutics, Inc. (NASDAQ: KYTX - Get Free Report) saw some unusual options trading on Monday. Investors purchased 2,529 call options on the company. This represents an increase of 900% compa
Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity
06:20pm, Monday, 15'th Dec 2025
Today, Dec. 15, 2025, stocks dipped as growth shares faltered and traders assessed trade risk alongside Fed commentary.
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 15'th Dec 2025
EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for pat
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome
12:06pm, Monday, 15'th Dec 2025
Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome, supporting a bullish outlook. KYTX's Miv-cel achieved significant clinical improvements and
Kyverna's cell therapy meets main goal of mid-stage study
06:42am, Monday, 15'th Dec 2025
Kyverna Therapeutics said on Monday its experimental cell therapy for treating patients with a rare movement disorder met the main goal of a mid-stage study, sending its shares surging 20% in premarke
Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
02:30pm, Sunday, 14'th Dec 2025
– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – – Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET –
Stock Picks From Seeking Alpha's November 2025 New Analysts
09:00am, Monday, 08'th Dec 2025
In November, Seeking Alpha welcomed 24 new analysts. This article introduces them and showcases some of their top picks. Analysts highlighted include The Academic Investor, recommending Galaxy Digital
Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential
02:24am, Friday, 14'th Nov 2025
Kyverna Therapeutics receives a strong buy rating with a $55 price target, driven by revolutionary Phase 2 data for KYV-101 in myasthenia gravis. KYV-101 demonstrated double the efficacy of standard c
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
04:05pm, Wednesday, 12'th Nov 2025
Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
08:00am, Monday, 10'th Nov 2025
EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients w
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
08:00am, Monday, 03'rd Nov 2025
Initial funding of $25 million from the first of four tranches Facility strengthens Kyverna's financial flexibility, further supporting advancement of its late-stage indications in generalized myast
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
06:30am, Wednesday, 29'th Oct 2025
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA)
